Press release: dupixent® (dupilumab) recommended for expanded eu approval by the chmp to treat children as young as six months old with severe atopic dermatitis

Dupixent ® (dupilumab) r ecommended for expanded eu a pproval by the chmp to t reat c hildren as young as six months old with s evere a topic d ermatitis
REGN Ratings Summary
REGN Quant Ranking